Sensodetect - Patent granted in China

Patent- BRAIN RESPONSE STATE-PC-CN in China has now been granted and Sensodetect have achieved the registreings and approval papers via the patent attorney AWA patent.

Patent describes how to calculate the neurons volatility or variance. This is not limited to detection only on the brain stem. The duration of a patent for invention is twenty years in China.

In all countries there is similar problems in Psychiatry as in Sweden and China is no exception. According to WHO, suffering approximately 25% of the world's population of mental ill-health. The queues to psychiatric care is growing rapidly in all parts of the world, therefore the need for new tools. Interest is increasing in mental health treatment where Sensodetect BERA can be used for "screening" or as a decision support is one strong possible tool. Even as a tool in research it is useful, for example, BERA, Sensodetect tool can be used to study different drug effects, etc. The now granted patents strengthens considerably the protection of Sensodetect in China, where there are several players who might be future competitors or stakeholders regarding SensoDetects platform BERA and the associated analytical tools.

"Sensodetect is strengthening its IP portfolio substantially on this gigantic market. Psychiatry is struggling with the same challenges as psychiatric care in Sweden, the queues are growing and the number of people affected increases. I am particularly happy when I see that the new patent relates to markets where we may well face new competitors and interested parties who see business opportunities in the area as Sensodetect operates. I therefore see this as a very important milestone that allows us to move forward our positions and seek partners on new large markets ", says CEO Johan Olson

 

Johan Olson

VD, SensoDetect Aktiebolag (publ)

Telefon: 046-151273

e-post: jo@sensodetect.com

  The information in this press release is such a Sensodetect AB is obligated to disclose in accordance with EU market abuse regulation. The information was submitted, through the above contact person's, for publication on May 11, 2017.

 

SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

Tags:

Subscribe

Documents & Links

Quotes

Sensodetect is strengthening its IP portfolio substantially on this gigantic market. Psychiatry is struggling with the same challenges as psychiatric care in Sweden, the queues are growing and the number of people affected increases. I am particularly happy when I see that the new patent relates to markets where we may well face new competitors and interested parties who see business opportunities in the area as Sensodetect operates. I therefore see this as a very important milestone that allows us to move forward our positions and seek partners on new large markets.
CEO, Johan Olson, Sensodetect AB (Publ.)